Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Featured
EMA backs extending Mounjaro to children with type-2 diabetes
On 11 December 2025 the EMA's CHMP recommended extending Mounjaro's licensed indication to adolescents and children aged 10 and over with insufficiently controlled type-2 diabetes.
TRIUMPH-1: retatrutide hits 28.3% weight loss at 80 weeks
Eli Lilly's first general-obesity Phase 3 readout for retatrutide: 28.3% mean body-weight reduction at 80 weeks on 12 mg weekly. Larger than any SURMOUNT-5 figure to date.
Latest
CagriSema REDEFINE 1 Target Analysis
A post hoc REDEFINE 1 analysis found more CagriSema participants reached BMI and waist-to-height targets, but the cutoffs need prospective validation.
GLP-1 Cardiovascular Umbrella Review
A 2026 umbrella review found stronger cardiovascular evidence in people with established disease, with more limited tirzepatide-specific certainty.
GLP-1 Drugs and NAION: A 2026 Review
A 2026 review found a rare NAION safety signal around GLP-1 medicines, led mainly by observational semaglutide data.
GLP-1 Drugs for Opioid Use Disorder?
A 2026 review traces GLP-1 addiction research from animal studies to early human signals, while completed randomized evidence remains sparse.
Dual Glucagon and GLP-1 Agonists: Review
A 2026 narrative review maps dual glucagon and GLP-1 agonists for obesity and MASH, while head-to-head evidence remains unresolved.
Ozempic Face and Facial Aging: 2026 Review
A 2026 dermatology review frames so-called Ozempic face as weight-loss-associated facial change, not a proven drug-specific diagnosis.
Incretin Therapy Before Pregnancy in PCOS
A target trial emulation linked preconception incretin therapy with fewer adverse pregnancy outcomes than metformin, but it cannot prove causation.
SELECT-Eligible MI Risk in Western Denmark
A Danish registry study found substantial five-year cardiovascular risk after a first heart attack among SELECT-eligible patients without diabetes.
SURMOUNT-OSA: Symptoms and Readouts
A SURMOUNT-OSA post hoc analysis found larger reported symptom gains from tirzepatide among people with worse symptoms at baseline.
Tirzepatide vs sleeve gastrectomy
A matched 2026 cohort compared 12-month weight loss after tirzepatide treatment or sleeve gastrectomy in severe obesity.
AI as a commercial health determinant
A BMJ commentary frames AI as a commercial determinant of health. Persuasion and misinformation studies show why the concern deserves testing.
Bariatric procedures vs semaglutide costs
A UK model compared sleeve gastroplasty, sleeve gastrectomy and a gastric balloon with semaglutide over five years.
Categories
Regulatory news
Agency actions, classification changes, enforcement letters and scheduling decisions across the EU, EEA, UK and US. Sourced to the primary regulator.
Trial readouts
What the latest Phase 2 and Phase 3 trials reported, the effect sizes that matter, and how to read the safety signals around them.
Expert digest
Credentialed experts on podcasts, in newsletters and at conferences, paraphrased with verbatim quotes, tier-coded for citation rigour.
Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
Comparison
Peptide-vs-peptide, country-vs-country, label-vs-grey-market. Methodology disclosed, conclusions tied to primary sources.
Vendor accountability
Counterfeit warnings, supply-chain incidents, Certificates of Analysis read in detail. We do not sell peptides and we do not promote vendors; we hold them to the same evidence bar as everyone else.
Methodology
How we score evidence depth, source recency and safety clarity. Behind-the-scenes editorial decisions. The reasoning, not just the result.
Country deep-dive
Single-country regulatory or market reports. How peptides actually move through Danish customs; what the BfArM said about a specific schedule shift; the German press response to a Mounjaro shortage.